Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialÁngela Lamarca, Juan W. Valle|The Lancet Oncology|2021Cited by 741
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upThierry Conroy, Michel Ducreux, Per Pfeiffer et al.|Annals of Oncology|2023Cited by 502
High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine TumorsJohan Botling, Joakim Crona, Ángela Lamarca et al.|Neuroendocrinology|2019Cited by 62
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectivesB. Ten Haaft, Ángela Lamarca, Manuel Pedregal et al.|European Journal of Cancer|2024Cited by 50
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumoursÁngela Lamarca, Juan W. Valle|Oncotarget|2018Cited by 35